Actinomycin D versus etoposide, methotrexate, actinomycin D/cyclophosphamide, and vincristine as second-line treatment in low-risk gestational trophoblastic neoplasia with primary methotrexate resistance
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Actinomycin D versus etoposide, methotrexate, actinomycin D/cyclophosphamide, and vincristine as second-line treatment in low-risk gestational trophoblastic neoplasia with primary methotrexate resistance. // International Journal of Gynecological Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1048891X26004354?dgcid=rss_sd_all
Actinomycin D versus etoposide, methotrexate, actinomycin D/cyclophosphamide, and vincristine as second-line treatment in low-risk gestational trophoblastic neoplasia with primary methotrexate resistance. International Journal of Gynecological Cancer. https://www.sciencedirect.com/science/article/pii/S1048891X26004354?dgcid=rss_sd_all
“Actinomycin D versus etoposide, methotrexate, actinomycin D/cyclophosphamide, and vincristine as second-line treatment in low-risk gestational trophoblastic neoplasia with primary methotrexate resistance.” International Journal of Gynecological Cancer.
@article{article116954,
title = {Actinomycin D versus etoposide, methotrexate, actinomycin D/cyclophosphamide, and vincristine as second-line treatment in low-risk gestational trophoblastic neoplasia with primary methotrexate resistance},
journal = {International Journal of Gynecological Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1048891X26004354?dgcid=rss_sd_all}
}